|Articles|April 5, 2023
Pharma USA 2023: IRA Impact on Patients
Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes to Medicare and how it positively effects patients.
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, participated on the Pharma USA 2023 panel "Post-Inflation Reduction Act: The continued need for patient assistance." Here he speaks to Pharmaceutical Executive about the IRA's impact on Medicare patients' affordability.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novartis Planning Layoffs for 550 Positions at Switzerland Facility
2
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
3
Aidoc Submits Breakthrough-Designated Multi-Triage Device for FDA Approval
4
Next-Gen CDMOs: Keeping Pace With Industry Change
5
